More recently, these genes together with BCOR, EZH2, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2 were recognized in the ICC as determinants for the entity of “AML with myelodysplasia-related gene mutations” irrespective of previous disease history [38], and the prognostic relevance of this entity was recognized in the ELN 2022 recommendations [27,39]. This evidence concerns the gene SRSF2 and acute myeloid leukemia.